Revelation Biosciences IncNASDAQ:REVB
- LAST PRICE1.5900
- TODAY'S CHANGE (%)-0.0300 (-1.8519%)
- Bid / Lots1.5800/ 11
- Ask / Lots1.6500/ 2
- Open / Previous Close1.6200 / 1.6200
- Day Range
- 52 Week Range
- Volume19,656
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | REVB |
|---|---|---|
| 09:32 ET | 114 | 1.62 |
| 09:38 ET | 124 | 1.6438 |
| 09:41 ET | 100 | 1.6221 |
| 09:48 ET | 200 | 1.63 |
| 09:50 ET | 300 | 1.6206 |
| 09:59 ET | 300 | 1.6267 |
| 10:46 ET | 100 | 1.6126 |
| 12:05 ET | 200 | 1.6375 |
| 12:07 ET | 100 | 1.63 |
| 12:12 ET | 737 | 1.64 |
| 12:39 ET | 3900 | 1.64 |
| 12:45 ET | 1224 | 1.62 |
| 12:48 ET | 766 | 1.6001 |
| 12:57 ET | 300 | 1.62 |
| 01:10 ET | 400 | 1.6206 |
| 01:12 ET | 424 | 1.6206 |
| 01:14 ET | 404 | 1.6201 |
| 01:26 ET | 1000 | 1.6201 |
| 01:32 ET | 100 | 1.6 |
| 01:51 ET | 300 | 1.61 |
| 02:06 ET | 1300 | 1.61 |
| 02:13 ET | 100 | 1.61 |
| 02:15 ET | 100 | 1.61 |
| 02:58 ET | 100 | 1.615 |
| 03:00 ET | 1265 | 1.6 |
| 03:02 ET | 400 | 1.61 |
| 03:21 ET | 500 | 1.6 |
| 03:30 ET | 799 | 1.59 |
| 03:39 ET | 136 | 1.6199 |
| 03:43 ET | 955 | 1.59 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Revelation Biosciences Inc | 2.6M | 0.0x | --- |
Innovation Pharmaceuticals Inc | 2.6M | 0.0x | --- |
Avenue Therapeutics Inc | 2.7M | -0.1x | --- |
Qrons Inc | 2.5M | -3.3x | --- |
Virax Biolabs Group Ltd | 2.8M | -0.9x | --- |
Biophytis SA | 2.3M | -0.1x | --- |
Company Information
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).
Contact Information
- Headquarters
- 4660 Lajolla Village Drive, Suite 100SAN DIEGO, CA, United States 92122
- Phone
- 650-800-3717
- Fax
- 302-645-1280
Executives
- Independent Chairman of the Board
- George Tidmarsh
- Chief Executive Officer, Co-Founder, Director
- James Rolke
- Chief Financial Officer
- Chester Zygmont
- Independent Director
- Jennifer Carver
- Independent Director
- Lakhmir Chawla
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.22 |
EPS | $-32.09 |
Book Value | $25.13 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
